| Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity L Vanderbeke, P Van Mol, Y Van Herck, F De Smet, S Humblet-Baron, ... Nature communications 12 (1), 4117, 2021 | 241 | 2021 |
| Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology I Vanmeerbeek, J Sprooten, D De Ruysscher, S Tejpar, P Vandenberghe, ... Oncoimmunology 9 (1), 1703449, 2020 | 221 | 2020 |
| Trial watch: dendritic cell vaccination for cancer immunotherapy J Sprooten, J Ceusters, A Coosemans, P Agostinis, S De Vleeschouwer, ... Oncoimmunology 8 (11), 1638212, 2019 | 145 | 2019 |
| Necroptosis in immuno-oncology and cancer immunotherapy J Sprooten, P De Wijngaert, I Vanmeerbeek, S Martin, P Vangheluwe, ... Cells 9 (8), 1823, 2020 | 139 | 2020 |
| Type I interferons and dendritic cells in cancer immunotherapy J Sprooten, P Agostinis, AD Garg International Review of Cell and Molecular Biology 348, 217-262, 2019 | 121 | 2019 |
| Trial watch: Dendritic cell (DC)-based immunotherapy for cancer RS Laureano, J Sprooten, I Vanmeerbeerk, DM Borras, J Govaerts, ... Oncoimmunology 11 (1), 2096363, 2022 | 96 | 2022 |
| Type I interferons and endoplasmic reticulum stress in health and disease J Sprooten, AD Garg International review of cell and molecular biology 350, 63-118, 2020 | 75 | 2020 |
| Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer S Naulaerts, A Datsi, DM Borras, A Antoranz Martinez, J Messiaen, ... Science Translational Medicine 15 (691), eadd1016, 2023 | 46 | 2023 |
| Trial watch: chemotherapy-induced immunogenic cell death in oncology J Sprooten, RS Laureano, I Vanmeerbeek, J Govaerts, S Naulaerts, ... Oncoimmunology 12 (1), 2219591, 2023 | 42 | 2023 |
| Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer J Sprooten, A Vankerckhoven, I Vanmeerbeek, DM Borras, Y Berckmans, ... Journal for Immunotherapy of Cancer 9 (11), e003609, 2021 | 35 | 2021 |
| Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer DM Borràs, S Verbandt, M Ausserhofer, G Sturm, J Lim, GA Verge, ... Cell Discovery 9 (1), 114, 2023 | 28 | 2023 |
| Identification of potential prognostic and predictive immunological biomarkers in patients with stage I and stage III non-small cell lung cancer (NSCLC): a prospective … RDW Vaes, K Reynders, J Sprooten, KT Nevola, KMA Rouschop, ... Cancers 13 (24), 6259, 2021 | 28 | 2021 |
| Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg Genes & Immunity 22 (2), 108-119, 2021 | 25 | 2021 |
| The interface of tumour-associated macrophages with dying cancer cells in immuno-oncology I Vanmeerbeek, J Govaerts, RS Laureano, J Sprooten, S Naulaerts, ... Cells 11 (23), 3890, 2022 | 20 | 2022 |
| Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells J Sprooten, I Vanmeerbeek, A Datsi, J Govaerts, S Naulaerts, ... Cell Reports Medicine 5 (1), 2024 | 18 | 2024 |
| Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy I Vanmeerbeek, S Naulaerts, J Sprooten, RS Laureano, J Govaerts, ... Science Advances 10 (29), eadm8660, 2024 | 10 | 2024 |
| A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma L Kinget, S Naulaerts, J Govaerts, I Vanmeerbeek, J Sprooten, ... Nature Medicine 30 (6), 1667-1679, 2024 | 10 | 2024 |
| The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy RS Laureano, I Vanmeerbeek, J Sprooten, J Govaerts, S Naulaerts, ... Immunological Reviews 321 (1), 71-93, 2024 | 9 | 2024 |
| Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy S Naulaerts, DM Borras, AA Martinez, J Messiaen, Y Van Herck, L Gelens, ... BioRxiv, 2021.11. 22.468617, 2021 | 7 | 2021 |
| A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology J Sprooten, A Coosemans, AD Garg Oncoimmunology 11 (1), 2024692, 2022 | 6 | 2022 |
